Appointments at DPT, PPD, Catalent and INC Research – People on the move

By Nick Taylor

- Last updated on GMT

Related tags Catalent pharma solutions Mds pharma services Management

Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at DPT, PPD, Catalent and INC Research.

DPT Laboratories ​has appointed Michael Curry​ as director of sterile operations at the company’s Center of Excellence for Sterile & Speciality Products in Lakewood, New Jersey, US.

Curry has 18 years experience in pharma and biotech, including periods at BioVigilant Systems, The Medicines Company, Dendreon, Wyeth, Baxter Bioscience and Schering-Plough.

Frank Gallo​ has joined PPD​ as executive director of risk management, strengthening its risk evaluation and mitigation strategies (REMS) operations. Gallo has more than 13 years experience in the sector, most recently at Rienzi & Rienzi, a healthcare communications firm.

Catalent Pharma Solutions ​has added two vice presidents (VP) of quality. Lois Johnson​ has been named as VP of quality, development and clinical services and Alex Eslava​ has been appointed as VP of quality, sterile technologies.

Before joining Catalent Johnson worked at Aptuit and has also held positions at Vertex Pharmaceuticals, Aventis Behring and Centeon. Eslava joins from Wyeth and has also worked at Amgen and Baxter Healthcare.

Richard Mark​ has joined INC Research​ as SVP of human resources. Mark has also worked at Baker & Taylor, Constellation Energy and Drexel Heritage Furnishings.

Aon Consulting ​has appointed Viq Pervaaz ​as SVP of corporate transactions. Before joining Aon Pervaaz was VP of global project management at MDS Pharma Services.

Lionel Delaporte ​has been named managing partner at Bionest Partners​, a provider of advisory and management services. Delaporte worked at Monitor, ISO and IMS Health before joining Bionest.

PriceSpective ​has appointed Steve O’Malley ​to lead its payer engagement practice. O’Malley has previously worked at Vertex Pharmaceuticals and Amylin Pharmaceuticals.

Related topics Markets & Regulations

Related news

Show more